In a patient with an A1c of 7.9% (up from 7.7%) who is taking tirzepatide (Mounjaro) 5 mg weekly and metformin 500 mg daily, which medication should be added?

Increase Mounjaro Dose to 10 mg or 15 mg

Before adding another medication, you should first titrate the Mounjaro (tirzepatide) to a higher dose, as the patient is currently on the starting dose of 5 mg. The metformin dose is also suboptimal at 500 mg daily. 1, 2, 3

Rationale for Dose Escalation

The A1C of 7.9% (up from 7.7%) indicates inadequate glycemic control, but the patient is on:

• Mounjaro 5 mg: This is the initial dose, not the maintenance dose. Tirzepatide should be escalated by 2.5 mg every 4 weeks until reaching the target maintenance dose 4
• Metformin 500 mg: This is below the typical therapeutic dose of 1500-2000 mg daily

Recommended Approach

Step 1: Optimize Current Medications

• Increase Mounjaro to 10 mg weekly (or 15 mg if 10 mg is insufficient after 3 months)
  • Tirzepatide doses of 10 mg and 15 mg reduce A1C by 2.20% and 2.37% respectively from baseline 5
  • The 5 mg dose is less effective, reducing A1C by only 1.93% 5
• Increase metformin to at least 1500-2000 mg daily (if tolerated)
  • Metformin should be continued and optimized unless contraindicated 1, 2, 3

Step 2: If Still Not at Goal After 3 Months

Only if A1C remains >7% after maximizing tirzepatide (15 mg) and metformin, then consider adding:

SGLT2 inhibitor (empagliflozin or canagliflozin) as the preferred add-on agent 1, 2

• Provides additional A1C reduction of 0.7-1.0% 3
• Offers cardiovascular and renal protection independent of glucose lowering 2, 6
• Low hypoglycemia risk
• Promotes additional weight loss

Alternative if SGLT2i contraindicated: Basal insulin (glargine U300 or degludec) 1, 3

• However, tirzepatide is superior to basal insulin for both A1C reduction and weight loss 5, 7, 8
• Consider fixed-ratio combination (insulin degludec + liraglutide or insulin glargine + lixisenatide) if both GLP-1RA and insulin are needed 2, 3

Key Clinical Pitfalls to Avoid

• Don't add medications prematurely: The patient hasn't reached the therapeutic dose of tirzepatide yet 4
• Don't add DPP-4 inhibitors: These should never be combined with GLP-1RAs like tirzepatide due to overlapping mechanisms without added benefit 3, 9
• Monitor for GI side effects: Nausea (14-26%), diarrhea (11-17%), and vomiting (5-13%) increase with dose escalation 4, 5
• Hypoglycemia risk is low: With tirzepatide alone or with metformin, severe hypoglycemia is rare (0.4 events per patient-year) 8

Expected Outcomes

With proper dose escalation to tirzepatide 10-15 mg:

• A1C reduction: Expect 2.0-2.4% decrease from baseline 5, 7
• Weight loss: 7.5-12.9 kg reduction 5, 7
• Achievement of A1C <7%: 82-93% of patients reach this target 5